Document is current
Any future updates will be listed below
-
Authors
Kendzia, Sandra
Franke, Susanne
Kröhler, Tarek
Golob-Schwarzl, Nicole
Schweiger, Caroline
Toeglhofer, Anna M.
Skofler, Christina
Uranitsch, Stefan
El-Heliebi, Amin
Fuchs, Julia
Punschart, Andreas
Stiegler, Philipp
Keil, Marlen
Hoffmann, Jens
Henderson, David
Lehrach, Hans
Yaspo, Marie-Laure
Reinhard, Christoph
Schäfer, Reinhold
Keilholz, Ulrich
Regenbrecht, Christian
Schicho, Rudolf
Fickert, Peter
Lax, Sigurd F.
Erdmann, Frank
Schulz, Marcel H.
Kiemer, Alexandra K.
Haybaeck, Johannes
Kessler, Sonja M.
-
Funding
Funding for this research was provided by:
Innovative Medicines Initiative Joint Undertaking (115234 (OncoTrack), 115234 (OncoTrack), 115234 (OncoTrack), 115234 (OncoTrack), 115234 (OncoTrack), 115234 (OncoTrack), 115234 (OncoTrack), 115234 (OncoTrack))
Wilhelm Sander-Stiftung (#2021.068.1)
Martin-Luther-Universität Halle-Wittenberg
- License Information
-
More Information
Article History
Received: 3 March 2023
Accepted: 11 May 2023
First Online: 30 May 2023
Declarations
:
: Tumor material was received with informed consent from 40 CRC patients from the St. John of God Hospital and the University Hospital Graz together with clinical information under approval by the ethics committees of the Medical University Graz and St. John of God Hospital (23–15 ex 1/11) [].
: The following authors are employees of the following pharmaceutical companies: Eli Lilly (C. Reinhard) and Bayer-Pharma (D.H.). Other authors are founder of Alacris Theranostics (H.L.), founder and CEO of CELLphenomics (C.R.), employee and/or shareholder of EPO (J. Hoffmann, M.K.). None of these companies influenced the interpretation of the data, or the data reported, or financially profit by the publication of the results. The remaining authors declare no competing financial interests.
